The dose schedule outlines the standard four-week intervals used in clinical trials
According to a STEP 1 clinical trial, most patients lost 3.8% of their body weight in the first month on 2.4 mg of semaglutide, when combined with increased physical activity and a reduced calorie diet
Women of reproductive age, individuals with pre-existing low iron stores, and those with heavy menstrual bleeding may be especially vulnerable to developing iron deficiency during Wegovy treatment through these indirect mechanisms
More recently, they gained approval for the treatment of obesity
Although short-term trials have shown promising results, as well as the obvious results that some people are sharing, the long-term data is needed to fully understand the potential risks
Because semaglutide is a potent medication, dosing errors, whether intentional or accidental, can lead to unintended exposure to higher amounts than planned and increase the risk of side effects